Sun Pharmaceutical Doxorubicin Hydrochloride Liposome Injection
DOXOrubin Hydrochloride Liposome injection contains glass particles that may cause irritation, swelling, blood vessel blockage, or life-threatening clots.
High risk
There is a reasonable chance that taking it could cause serious health problems or death.
FDA Class I recall · How risk is rated
2 photos
What happened
If administered intravenously, they may cause local irritation or swelling, and more serious risks include blockage of blood vessels and life-threatening blood clot events. No adverse events have been reported to date.
What to do
If a code on your package matches:
- Distributors/retailers/hospitals/users that have the product should stop using.
- Return to place of purchase or discard the product.
- Contact your physician or healthcare provider if you have experienced any problems that may be related to taking or using this drug product.
- Customers with questions regarding this recall can contact Inmar Inc., (Sun Pharma’s recall processor) by 855-745-9357, Monday through Friday between 8:30 am and 5:00 pm, U.S. Eastern Time, or via rxrecalls@
inmar.com.
Is yours affected?
Match the NDC, lot code and best-by date listed under your product.
DOXOrubin Hydrochloride Liposome injection
- NDC
- 72603-200-01
- Lot code
- HAG2581B
- Best-by
- 05/2027
Details
- Company began the recall
- Sold in
U.S. Nationwide
- Event ID
- 98921
- Recall No.
- D-0580-2026
- Company
- SUN PHARMACEUTICAL INDUSTRIES INCPrinceton, New Jersey
- Hazard
- Foreign material
- Quantity recalled
- 675 vials
Company began the recall
Announced by the company
Listed on Recall Canary
Added to FDA's Enforcement Report · Classified by FDA
In FDA's weekly enforcement report
Summary updated
